scholarly article | Q13442814 |
P819 | ADS bibcode | 2011PLoSO...625132R |
P356 | DOI | 10.1371/JOURNAL.PONE.0025132 |
P932 | PMC publication ID | 3180374 |
P698 | PubMed publication ID | 21966435 |
P5875 | ResearchGate publication ID | 51687556 |
P50 | author | Jatin Roper | Q57659291 |
P2093 | author name string | Wei Chen | |
Roderick T Bronson | |||
Peng-Chieh Chen | |||
Kenneth E Hung | |||
Lydia Lee | |||
Eric S Martin | |||
Erin M Coffee | |||
Mark J Sinnamon | |||
Wei Vivian Wang | |||
Michael P Richardson | |||
Larissa Georgeon Richard | |||
P2860 | cites work | Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1 | Q24531380 |
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 | ||
mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 | ||
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas | Q24646237 | ||
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations | Q24646816 | ||
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations | Q27851644 | ||
Cancer statistics, 2010 | Q27860525 | ||
High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
Defining the role of mTOR in cancer | Q28235431 | ||
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha | Q28616168 | ||
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha | Q30437618 | ||
mTOR and cancer: many loops in one pathway. | Q33348248 | ||
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 | ||
Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment | Q33667595 | ||
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas | Q33896731 | ||
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs | Q33901504 | ||
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo | Q33939369 | ||
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma | Q34001234 | ||
Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells | Q34480703 | ||
The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma | Q34522360 | ||
The role of mTORC1 pathway in intestinal tumorigenesis. | Q43255342 | ||
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. | Q46047974 | ||
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging | Q46431103 | ||
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. | Q46708758 | ||
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. | Q53568151 | ||
Systemic treatment of colorectal cancer | Q81253030 | ||
The two TORCs and Akt. | Q34617423 | ||
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma | Q34810176 | ||
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers | Q34970844 | ||
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib | Q35177682 | ||
Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy | Q35556966 | ||
The mighty mouse: genetically engineered mouse models in cancer drug development | Q36568461 | ||
Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice | Q36869970 | ||
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 | ||
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance | Q37036297 | ||
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. | Q37177892 | ||
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis | Q37242436 | ||
PTEN and the PI3-kinase pathway in cancer | Q37259680 | ||
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations | Q37382669 | ||
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. | Q37396608 | ||
Mouse models of colon cancer | Q37407244 | ||
Phosphoinositide signalling in cancer: beyond PI3K and PTEN. | Q37736257 | ||
Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines | Q39513509 | ||
Levels of p27 sensitize to dual PI3K/mTOR inhibition | Q39529578 | ||
The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. | Q39557570 | ||
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways | Q39571848 | ||
Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor | Q39591379 | ||
The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. | Q39636381 | ||
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. | Q39650704 | ||
Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. | Q39653276 | ||
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease | Q39720433 | ||
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. | Q39744205 | ||
NVP-BEZ235 as a new therapeutic option for sarcomas. | Q39752874 | ||
Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models | Q39763382 | ||
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 | ||
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. | Q39832054 | ||
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma | Q39906851 | ||
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model | Q40182123 | ||
Mutant PIK3CA promotes cell growth and invasion of human cancer cells | Q40410776 | ||
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. | Q42081736 | ||
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. | Q42282551 | ||
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition | Q42452282 | ||
NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. | Q43055104 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | colorectal cancer | Q188874 |
colorectal carcinoma | Q25493920 | ||
P304 | page(s) | e25132 | |
P577 | publication date | 2011-09-26 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer | |
P478 | volume | 6 |
Q35987253 | AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis |
Q33999493 | Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status |
Q34188530 | Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells |
Q36985432 | Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells |
Q35321647 | Cell specific apoptosis by RLX is mediated by NFκB in human colon carcinoma HCT-116 cells |
Q47558200 | Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. |
Q42085487 | Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer |
Q27852136 | Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer |
Q50027355 | Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer |
Q38824026 | Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit. |
Q38080710 | Development of PI3K inhibitors: lessons learned from early clinical trials |
Q37632641 | Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. |
Q64055917 | EMT Regulation by Autophagy: A New Perspective in Glioblastoma Biology |
Q33934922 | Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways |
Q89156992 | Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells |
Q34332175 | Genetically engineered mouse models of PI3K signaling in breast cancer |
Q28534803 | Genotype directed therapy in murine mismatch repair deficient tumors |
Q38705367 | In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis |
Q39255433 | Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells |
Q34182679 | MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma |
Q92059453 | Mouse models of colorectal cancer: Past, present and future perspectives |
Q89558411 | NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation |
Q35063769 | NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation |
Q34679652 | NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro |
Q37660260 | Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions. |
Q26781367 | PI3K and AKT: Unfaithful Partners in Cancer |
Q37727180 | PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes |
Q40509393 | PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. |
Q55518346 | PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. |
Q47128334 | PKM2 is not required for colon cancer initiated by APC loss. |
Q52310328 | PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT. |
Q41472038 | PTRF suppresses the progression of colorectal cancers. |
Q35987363 | PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer |
Q26766292 | Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics |
Q89036516 | Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer |
Q91745562 | Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma |
Q33776641 | Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development |
Q39067602 | Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. |
Q57477082 | Sodium tanshinone IIA sulfonate protects ARPE-19 cells against oxidative stress by inhibiting autophagy and apoptosis |
Q28396388 | Sustained proliferation in cancer: Mechanisms and novel therapeutic targets |
Q39735209 | Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis |
Q42360077 | Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer |
Q92550221 | Targeting Akt by SC66 triggers GSK-3β mediated apoptosis in colon cancer therapy |
Q38105322 | Targeting PI3K in Cancer: Any Good News? |
Q38375141 | Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond |
Q37708005 | Targeting mTOR network in colorectal cancer therapy |
Q38121524 | Targeting the mTOR signaling network for Alzheimer's disease therapy |
Q26744721 | The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer |
Q38043507 | The promise of mTOR inhibitors in the treatment of colorectal cancer |
Q37687348 | The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance |
Q89846048 | The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis |
Q91716178 | Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer |
Q38946538 | Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress. |
Q38208069 | Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations |
Q38042938 | Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer |
Q36471425 | Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population |
Q64274877 | mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy |
Q37649634 | mTOR pathway in colorectal cancer: an update |